BACKGROUND AND OBJECTIVES: Prescription patterns for hemodialysis patients with secondary hyperparathyroidism have varied widely since market introduction of cinacalcet. This study examined associations between prescription patterns and subsequent laboratory values. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using a Mineral and Bone Disorder Outcomes Study for Japanese CKD Stage 5D Patients subcohort, 1716 prevalent hemodialysis patients (4048 sets for repeated measures between January 2008 and July 2009) with an intact parathyroid hormone (iPTH) level >180 pg/ml who used intravenous vitamin D receptor activator (VDRA) without cinacalcet were selected. Prescription patterns were defined based on cinacalcet administration (starting or not) and VDRA dosage change (decreased [<-25%], stable [-25% to 25%], or increased [>25%]). Proportion differences (PDs) were determined for decreasing iPTH levels by at least one category (<180, 180-299, 300-499, and ≥500 pg/ml) and for achieving target phosphorus (3.5-6.0 mg/dl) and calcium (8.4-10.0 mg/dl) levels, adjusting for potential confounders. RESULTS: The starting cinacalcet and increased VDRA patterns were associated with decreasing iPTH levels (PD, 0.25 and 0.13; 95% confidence intervals [95% CIs], 0.19-0.31 and 0.09-0.17, respectively); combination use had an additive association (PD, 0.34; 95% CI, 0.20-0.42). The starting cinacalcet and decreased VDRA combination was associated with simultaneously achieving target phosphorus (PD, 0.12; 95% CI: 0.04-0.20) and calcium (PD, 0.09; 95% CI, 0.01-0.17) levels. CONCLUSIONS: Certain combinations of cinacalcet and VDRA were associated with decreasing iPTH and achieving targets for phosphorus and calcium. Combinations may prove advantageous versus VDRA alone in managing secondary hyperparathyroidism.
BACKGROUND AND OBJECTIVES: Prescription patterns for hemodialysis patients with secondary hyperparathyroidism have varied widely since market introduction of cinacalcet. This study examined associations between prescription patterns and subsequent laboratory values. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using a Mineral and Bone Disorder Outcomes Study for Japanese CKD Stage 5D Patients subcohort, 1716 prevalent hemodialysis patients (4048 sets for repeated measures between January 2008 and July 2009) with an intact parathyroid hormone (iPTH) level >180 pg/ml who used intravenous vitamin D receptor activator (VDRA) without cinacalcet were selected. Prescription patterns were defined based on cinacalcet administration (starting or not) and VDRA dosage change (decreased [<-25%], stable [-25% to 25%], or increased [>25%]). Proportion differences (PDs) were determined for decreasing iPTH levels by at least one category (<180, 180-299, 300-499, and ≥500 pg/ml) and for achieving target phosphorus (3.5-6.0 mg/dl) and calcium (8.4-10.0 mg/dl) levels, adjusting for potential confounders. RESULTS: The starting cinacalcet and increased VDRA patterns were associated with decreasing iPTH levels (PD, 0.25 and 0.13; 95% confidence intervals [95% CIs], 0.19-0.31 and 0.09-0.17, respectively); combination use had an additive association (PD, 0.34; 95% CI, 0.20-0.42). The starting cinacalcet and decreased VDRA combination was associated with simultaneously achieving target phosphorus (PD, 0.12; 95% CI: 0.04-0.20) and calcium (PD, 0.09; 95% CI, 0.01-0.17) levels. CONCLUSIONS: Certain combinations of cinacalcet and VDRA were associated with decreasing iPTH and achieving targets for phosphorus and calcium. Combinations may prove advantageous versus VDRA alone in managing secondary hyperparathyroidism.
Authors: Mark D Danese; John Kim; Quan V Doan; Michelle Dylan; Robert Griffiths; Glenn M Chertow Journal: Am J Kidney Dis Date: 2006-01 Impact factor: 8.860
Authors: K Kalantar-Zadeh; N Kuwae; D L Regidor; C P Kovesdy; R D Kilpatrick; C S Shinaberger; C J McAllister; M J Budoff; I B Salusky; J D Kopple Journal: Kidney Int Date: 2006-07-05 Impact factor: 10.612
Authors: Jill S Lindberg; Bruce Culleton; Gordon Wong; Michael F Borah; Roderick V Clark; Warren B Shapiro; Simon D Roger; Fred E Husserl; Preston S Klassen; Matthew D Guo; Moetaz B Albizem; Jack W Coburn Journal: J Am Soc Nephrol Date: 2005-02-02 Impact factor: 10.121
Authors: M Jadoul; J M Albert; T Akiba; T Akizawa; L Arab; J L Bragg-Gresham; N Mason; K-G Prutz; E W Young; R L Pisoni Journal: Kidney Int Date: 2006-08-23 Impact factor: 10.612
Authors: Sharon M Moe; Glenn M Chertow; Jack W Coburn; L Darryl Quarles; William G Goodman; Geoffrey A Block; Tilman B Drüeke; John Cunningham; Donald J Sherrard; Laura C McCary; Kurt A Olson; Stewart A Turner; Kevin J Martin Journal: Kidney Int Date: 2005-02 Impact factor: 10.612
Authors: Piergiorgio Messa; Fernando Macário; Magdi Yaqoob; Koen Bouman; Johann Braun; Beat von Albertini; Hans Brink; Francisco Maduell; Helmut Graf; João M Frazão; Willem Jan Bos; Vicente Torregrosa; Heikki Saha; Helmut Reichel; Martin Wilkie; Valter J Zani; Bart Molemans; Dave Carter; Francesco Locatelli Journal: Clin J Am Soc Nephrol Date: 2008-01 Impact factor: 8.237
Authors: Francesca Tentori; Mia Wang; Brian A Bieber; Angelo Karaboyas; Yun Li; Stefan H Jacobson; Vittorio E Andreucci; Masafumi Fukagawa; Luc Frimat; David C Mendelssohn; Friedrich K Port; Ronald L Pisoni; Bruce M Robinson Journal: Clin J Am Soc Nephrol Date: 2014-12-16 Impact factor: 8.237